GO
Loading...

Latest Video

Contact Latest Video

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Video and TV

Wednesday, 23 Apr 2014 | 9:19 AM ET

Activist investor Carl Icahn comments on Bill Ackman's role in the Valeant Pharmaceuticals bid for Allergan. The "Squawk on the Street" team provide insight.

Wednesday, 23 Apr 2014 | 9:17 AM ET

The "Squawk on the Street" news team discuss the involvement of Bill Ackman in the deal between Valeant Pharmaceuticals and Allergan.

Wednesday, 23 Apr 2014 | 7:48 AM ET

William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.

U.S. Video

  • Weekly jobless claims and durable goods are the numbers to watch Thursday, but so are the massive amount of earnings reports expected. CNBC's Patti Domm explains.

  • Discussing Apple's 7-for-1 stock split effective June 9, and the company's bad tablet number, with Max Wolff, Citizen VC chief economist, and Gene Munster, Piper Jaffray senior research analyst.

  • Apple is reporting Q2 EPS of $11.62 on revenue of $45.6 billion. Gene Munster, Piper Jaffray senior research analyst, says investors should feel a sense of relief on these numbers.

Asia Video

Europe Video

Most Popular Video

Wednesday, 23 Apr 2014 | 1:00 PM ET

CNBC's Kelli Grant talks about the types of protection available to credit and debit card holders in the transition to a cashless society.

Wednesday, 23 Apr 2014 | 12:00 PM ET

Rumors of a delayed Apple iPhone 6 product launch and a larger display screen are swirling about the technosphere, with Lindsey Turrentine, CNET editor-in-chief.

Wednesday, 23 Apr 2014 | 11:40 AM ET

CNBC's Bob Pisani and Art Cashin, of UBS, discuss anticipation for Apple and Facebook's earnings, and the yield on the 10-year Treasury yield.